1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals

BACKGROUND: The Antibody-mediated Prevention (AMP) trials (HVTN 704/HPTN 085 and HVTN 703/HPTN 081) are the first efficacy trials to evaluate whether VRC01, a broadly neutralizing antibody (bnAb) that targets CD4 binding site of HIV envelope, prevents HIV acquisition in uninfected individuals. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Edupuganti, Srilatha, Mgodi, Nyaradzo M, Karuna, Shelly, Andrew, Philip, Kochar, Nidhi, Marshall, Kyle, Decamp, Allan, Takuva, Simbarashe, Anderson, Maija, De La Grecca, Robert, Gomez Lorenzo, Margarita, Burns, David, Goepfert, Paul, McElrath, Julie, Casapia, Martin, Sanchez, Jorge, Mukwekwerere, Pamela G, Shava, Emily, Lazarus, Erica M, Hural, John, Mascola, John R, Cohen, Myron, Corey, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808666/
http://dx.doi.org/10.1093/ofid/ofz360.1135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808666/
http://dx.doi.org/10.1093/ofid/ofz360.1135

Ejemplares similares